In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
Several Phase 1 and Phase 2 trials report encouraging results this month, amplifying momentum in precision psychiatry, respiratory …
The European Commission launched several new funding opportunities under its Horizon Europe “Health” cluster to boost innovation in …
Phase III SEQUOIA-HCM analyses show aficamten offers benefit to patients with varying symptom severity and across regions, opening …
Regulatory nod gives push to a potentially powerful combination in acute myeloid leukaemia
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
FORECAST-2 trial pioneers the use of tumor organoids for personalized treatment selection in bowel cancer, aiming to revolutionize …
Botensilimab and balstilimab combinations deliver unprecedented tumor responses across multiple cancer types, fueling optimism for harder-to-treat colorectal, breast, …
In a world-first, an infant with a fatal genetic disorder receives a custom, in vivo CRISPR therapy, showcasing …
Breakthroughs in personalized therapies and AI-driven tools are reshaping how cancer is diagnosed and treated, promising better outcomes …
Already a subscriber? Log in